NEOS Investment Management LLC Buys 10,113 Shares of DexCom, Inc. (NASDAQ:DXCM)

NEOS Investment Management LLC boosted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 15.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 76,172 shares of the medical device company’s stock after acquiring an additional 10,113 shares during the period. NEOS Investment Management LLC’s holdings in DexCom were worth $5,924,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the company. Forvis Mazars Wealth Advisors LLC raised its position in shares of DexCom by 0.7% during the 4th quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company’s stock valued at $1,359,000 after purchasing an additional 118 shares during the period. Principal Securities Inc. increased its stake in DexCom by 3.4% in the 4th quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company’s stock worth $316,000 after buying an additional 135 shares in the last quarter. Larson Financial Group LLC raised its holdings in DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after acquiring an additional 137 shares during the period. TD Private Client Wealth LLC lifted its position in shares of DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 167 shares in the last quarter. Finally, GPS Wealth Strategies Group LLC lifted its position in shares of DexCom by 13.2% in the fourth quarter. GPS Wealth Strategies Group LLC now owns 1,587 shares of the medical device company’s stock valued at $123,000 after acquiring an additional 185 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Stock Down 3.7 %

Shares of NASDAQ DXCM opened at $69.47 on Friday. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $141.99. The firm has a 50-day simple moving average of $82.65 and a two-hundred day simple moving average of $77.02. The company has a market cap of $27.15 billion, a P/E ratio of 48.58, a PEG ratio of 2.30 and a beta of 1.28. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Buying and Selling at DexCom

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the sale, the chief operating officer now directly owns 268,644 shares of the company’s stock, valued at $23,347,850.04. The trade was a 0.97 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now directly owns 319,037 shares in the company, valued at $27,727,505.67. The trade was a 9.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 105,009 shares of company stock valued at $8,044,178 in the last three months. Company insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on DXCM. Wells Fargo & Company reissued an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Morgan Stanley upped their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Cfra Research upgraded shares of DexCom to a “hold” rating in a report on Friday, March 21st. Finally, Citigroup increased their price objective on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a report on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $99.82.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.